REGENXBIO 10-Q Flags Going-Concern Doubt Despite $251M Cash
RGNX sits 47% above its 52-week low of $5.455.
Summary
REGENXBIO's Q3 10-Q formally flags substantial doubt about its ability to continue as a going concern, even with $251.0 million in cash and securities plus $39.0 million of October settlement proceeds that fund operations into late Q4 2027. Revenue fell to $9.2 million as Zolgensma royalties dropped $21.2 million after U.S. patent expiry.
Key Events · Earnings and Guidance · RGNX
-
Going-Concern Doubt Disclosed
The 10-Q states that conditions 'raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued.'
-
Cash Funds Operations Into Late Q4 2027
Cash, cash equivalents and marketable securities were $251.0 million at September 30, 2026, and exclude the $39.0 million Sarepta settlement received in October 2026.
-
Revenue Collapses on Zolgensma Patent Expiry
Q3 2026 revenue was $9.2 million versus $29.7 million a year earlier; Zolgensma royalties fell $21.2 million to $2.4 million after U.S. licensed patents expired in January 2026, partly offset by $2.8 million of new Itvisma royalties.
-
Loss Narrows on Sarepta Settlement Gain
Net loss was $40.7 million ($0.62 per share) versus $61.9 million ($1.20) a year earlier, helped by a $38.0 million gain on the Sarepta litigation settlement; nine-month operating cash burn rose to $99.8 million from $71.7 million.
Analysis · RGNX · Life Sciences
The headline numbers were already out this morning, but the full 10-Q carries the sentence that matters: management says conditions 'raise substantial doubt about the Company's ability to continue as a going concern within 12 months.' That is a formal going-concern flag, not boilerplate risk-factor language, and it lands on a company whose revenue base is collapsing. Zolgensma royalties fell $21.2 million year over year to $2.4 million after U.S. patent expiry in January 2026, leaving total Q3 revenue at $9.2 million against $61.0 million of R&D spend. The $251.0 million cash pile plus the $39.0 million Sarepta settlement received in October buys time into late Q4 2027, but the clock is now explicit and tied to binary events: RGX-202 BLA submission targeted for Q1 2027 and wet AMD pivotal data due Q4 2026. Any financing before then is likely to be dilutive at current levels.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGNX was trading at $8.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $509M. The 52-week trading range was $5.46 to $16.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.